Orum Therapeutics Corrects Stock Option Exercise Deadline to October 2031 From October 2036

• Orum Therapeutics corrected its shareholder meeting notice on Oct. 22, 2026, shortening Geoffrey Harris Meyerson’s stock option exercise period.
• The corrected period runs from Oct. 24, 2028, through Oct. 23, 2031, rather than Oct. 23, 2036.
• The U.S. subsidiary’s proposed 85,663-share option grant comprises 73,741 shares for CSO Chad May and 11,922 shares for three employees.
• A previously omitted March 27, 2026, grant of 102,223 shares raises total options granted across the reported periods to 799,964 shares.
• Remaining options across those periods were corrected to 729,780 shares from 627,557 shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orum Therapeutics Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261022000137), on October 22, 2026, and is solely responsible for the information contained therein.